Immunotherapy in Head and Neck Squamous Cell Cancer
Clinical and Experimental Otorhinolaryngology
;
: 217-223, 2018.
Artículo
en Inglés
| WPRIM
| ID: wpr-718515
ABSTRACT
Prognosis in relapsed metastatic head and neck squamous cell cancer (RM-HNSCC) is dismal. Platinum based chemotherapy in combination with Cetuximab is used in first-line setting, while no further validated options are available at progression. Immunotherapy has produced durable clinical benefit in some patients with RM-HNSCC although the premises are several patients are nonresponders. Studies are ongoing to determine predictive factors and the ideal setting/combination of novel immunotherapies. In this paper, we discuss the past and present of immunotherapy in head and neck cancer and provide an up-to-date information regarding the potential ways to improve immunotherapy outcomes in HNSCC.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Platino (Metal)
/
Pronóstico
/
Carcinoma de Células Escamosas
/
Biomarcadores
/
Neoplasias de Células Escamosas
/
Escape del Tumor
/
Quimioterapia
/
Células Epiteliales
/
Cetuximab
/
Cabeza
Tipo de estudio:
Estudio pronóstico
Límite:
Humanos
Idioma:
Inglés
Revista:
Clinical and Experimental Otorhinolaryngology
Año:
2018
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS